Independence Blue Cross and the Colorectal Cancer Alliance announced a cancer screening and prevention program which aims to address the decrease in colorectal cancer screening rates among Black Philadelphians since the pandemic started.
Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.
